B. Riley Says Alzheimer's Data From This Firm Has Renewed 'Investor Confidence'

  • B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's SAVA simufilam trial data "reinvigorate" investor confidence. 
  • The Company announced a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease.
  • Related Content: Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease.
  • Analyst Mayank Mamtani has reiterated a Buy rating with a $108 price target.
  • Mamtani tells investors in a research note that this cognition data update and evaluation methodology "to some extent, helps assuage investor concerns" emanating from the recent Citizen's Petition.
  • Related: Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy.
  • But the analyst still asserts that the Company needs supportive 12-month biomarker analyses.
  • Price Action: SAVA stock is up 16.20% at $60.71 during the market session on the last check Thursday.
Loading...
Loading...
SAVA Logo
SAVACassava Sciences Inc
$2.08-0.48%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
1.11
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...